Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.
Identifieur interne : 002C52 ( Main/Exploration ); précédent : 002C51; suivant : 002C53Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.
Auteurs : Patrick D. Mcgorry [Australie] ; John Cocks ; Paddy Power ; Peter Burnett ; Susy Harrigan ; Tim LambertSource :
- Schizophrenia research and treatment [ 2090-2093 ] ; 2011.
Abstract
Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs) when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this population. Here, we report the results of a biphasic open label trial designed to assess the efficacy, safety, and tolerability of low-dose (2-4 mg/day) risperidone treatment in a group of 96 first-episode nonaffective psychosis patients. At the end of the trial, 62% of patients met the response criteria although approximately 80% had achieved a response at some time during the study. Reports of EPS remained low, and there were no dystonic reactions. We conclude that even at a dose of 2 mg/day, risperidone was highly effective in reducing acute symptomatology in a real world sample of young first-episode psychosis patients.
DOI: 10.1155/2011/631690
PubMed: 22937271
PubMed Central: PMC3428615
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.</title><author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name><affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen Youth Health Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, VIC 3052</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Cocks, John" sort="Cocks, John" uniqKey="Cocks J" first="John" last="Cocks">John Cocks</name></author><author><name sortKey="Power, Paddy" sort="Power, Paddy" uniqKey="Power P" first="Paddy" last="Power">Paddy Power</name></author><author><name sortKey="Burnett, Peter" sort="Burnett, Peter" uniqKey="Burnett P" first="Peter" last="Burnett">Peter Burnett</name></author><author><name sortKey="Harrigan, Susy" sort="Harrigan, Susy" uniqKey="Harrigan S" first="Susy" last="Harrigan">Susy Harrigan</name></author><author><name sortKey="Lambert, Tim" sort="Lambert, Tim" uniqKey="Lambert T" first="Tim" last="Lambert">Tim Lambert</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22937271</idno><idno type="pmid">22937271</idno><idno type="doi">10.1155/2011/631690</idno><idno type="pmc">PMC3428615</idno><idno type="wicri:Area/Main/Corpus">002F66</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">002F66</idno><idno type="wicri:Area/Main/Curation">002F66</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">002F66</idno><idno type="wicri:Area/Main/Exploration">002F66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.</title><author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name><affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen Youth Health Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, VIC 3052</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Cocks, John" sort="Cocks, John" uniqKey="Cocks J" first="John" last="Cocks">John Cocks</name></author><author><name sortKey="Power, Paddy" sort="Power, Paddy" uniqKey="Power P" first="Paddy" last="Power">Paddy Power</name></author><author><name sortKey="Burnett, Peter" sort="Burnett, Peter" uniqKey="Burnett P" first="Peter" last="Burnett">Peter Burnett</name></author><author><name sortKey="Harrigan, Susy" sort="Harrigan, Susy" uniqKey="Harrigan S" first="Susy" last="Harrigan">Susy Harrigan</name></author><author><name sortKey="Lambert, Tim" sort="Lambert, Tim" uniqKey="Lambert T" first="Tim" last="Lambert">Tim Lambert</name></author></analytic><series><title level="j">Schizophrenia research and treatment</title><idno type="eISSN">2090-2093</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs) when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this population. Here, we report the results of a biphasic open label trial designed to assess the efficacy, safety, and tolerability of low-dose (2-4 mg/day) risperidone treatment in a group of 96 first-episode nonaffective psychosis patients. At the end of the trial, 62% of patients met the response criteria although approximately 80% had achieved a response at some time during the study. Reports of EPS remained low, and there were no dystonic reactions. We conclude that even at a dose of 2 mg/day, risperidone was highly effective in reducing acute symptomatology in a real world sample of young first-episode psychosis patients.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22937271</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2090-2093</ISSN><JournalIssue CitedMedium="Internet"><Volume>2011</Volume><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Schizophrenia research and treatment</Title><ISOAbbreviation>Schizophr Res Treatment</ISOAbbreviation></Journal><ArticleTitle>Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.</ArticleTitle><Pagination><MedlinePgn>631690</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2011/631690</ELocationID><Abstract><AbstractText>Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs) when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this population. Here, we report the results of a biphasic open label trial designed to assess the efficacy, safety, and tolerability of low-dose (2-4 mg/day) risperidone treatment in a group of 96 first-episode nonaffective psychosis patients. At the end of the trial, 62% of patients met the response criteria although approximately 80% had achieved a response at some time during the study. Reports of EPS remained low, and there were no dystonic reactions. We conclude that even at a dose of 2 mg/day, risperidone was highly effective in reducing acute symptomatology in a real world sample of young first-episode psychosis patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGorry</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Orygen Youth Health Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocks</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Paddy</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Harrigan</LastName><ForeName>Susy</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>Schizophr Res Treatment</MedlineTA><NlmUniqueID>101576450</NlmUniqueID><ISSNLinking>2090-2093</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22937271</ArticleId><ArticleId IdType="doi">10.1155/2011/631690</ArticleId><ArticleId IdType="pmc">PMC3428615</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychiatry. 2001 Apr;62(4):282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11379843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2006 Apr;40(4):626-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16569802</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Oct;162(10):1785-804</Citation><ArticleIdList><ArticleId IdType="pubmed">16199825</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1993;110(3):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7530376</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1992;28(1):81-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1609046</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Nov;59(11):1002-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12418933</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1997 Aug;17(4):308-13</Citation><ArticleIdList><ArticleId IdType="pubmed">9241011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003834</Citation><ArticleIdList><ArticleId IdType="pubmed">17636738</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jan;59(1):62-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11779284</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Aug;48(8):739-45</Citation><ArticleIdList><ArticleId IdType="pubmed">1883257</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2009 May;19(5):1107-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18842668</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):585-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12796222</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Oct 1;46(7):929-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10509176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Dec;68(12):1867-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18162017</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 Mar;3(2):135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9577837</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Oct;63(10):885-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12416598</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2006 Aug;40(8):616-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16866756</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Oct 1;56(7):467-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15450781</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2008 Oct;7(3):148-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18836582</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1989;25(1):92-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2772122</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 1998 Jan-Feb;20(1):58-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9522104</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Sep;61(9):638-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11030483</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">16461856</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Apr;62(4):361-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15809403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003;64 Suppl 16:10-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14680413</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1996;22(2):305-26</Citation><ArticleIdList><ArticleId IdType="pubmed">8782288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1999;25(4):721-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10667742</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 May;162(5):947-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15863797</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 1998;172(33):66-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9764129</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Aug;160(8):1396-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12900300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1994 May;55 Suppl:5-12</Citation><ArticleIdList><ArticleId IdType="pubmed">7520908</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Jun;44(6):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15908839</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Nov;156(11):1686-96</Citation><ArticleIdList><ArticleId IdType="pubmed">10553730</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Sep;33(10):2467-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18199999</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Jul;153(7):948-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8659621</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2008 Jul;29(7):346-51</Citation><ArticleIdList><ArticleId IdType="pubmed">18538422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2008 Mar 29;371(9618):1085-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18374841</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1995;57(10):PL103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7543969</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2004 Apr;24(2):220-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15206670</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):975-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16143729</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1984;10(3):388-98</Citation><ArticleIdList><ArticleId IdType="pubmed">6474101</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2010 May;196(5):377-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20435964</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Sep;35(5):909-18</Citation><ArticleIdList><ArticleId IdType="pubmed">19509308</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1999 Mar;44(2):164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10097837</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Jun;156(6):869-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10360125</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Feb 15;82(1):89-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16413757</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Burnett, Peter" sort="Burnett, Peter" uniqKey="Burnett P" first="Peter" last="Burnett">Peter Burnett</name><name sortKey="Cocks, John" sort="Cocks, John" uniqKey="Cocks J" first="John" last="Cocks">John Cocks</name><name sortKey="Harrigan, Susy" sort="Harrigan, Susy" uniqKey="Harrigan S" first="Susy" last="Harrigan">Susy Harrigan</name><name sortKey="Lambert, Tim" sort="Lambert, Tim" uniqKey="Lambert T" first="Tim" last="Lambert">Tim Lambert</name><name sortKey="Power, Paddy" sort="Power, Paddy" uniqKey="Power P" first="Paddy" last="Power">Paddy Power</name></noCountry><country name="Australie"><region name="Victoria (État)"><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22937271
|texte= Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22937271" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |